Journal
ADVANCED MATERIALS
Volume 31, Issue 49, Pages -Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/adma.201904329
Keywords
multimodal imaging; nanomaterials; nanotechnology; precision surgery; synergistic therapy
Categories
Funding
- National Natural Science Foundation of China [81970569, 81773293, 31660266]
- Natural Science Foundation of Hu'nan Province, China [2015JJ4083, 2018JJ3758]
- Key Research and Development Program of Hu'nan Provincial Science and Technology Department, China [2017DK2011, 2017WK2060, 2015GK3117]
- Hu'nan Provincial Traditional Chinese Medicine Research Project [201869, 201951]
- Progress and Innovation Project of Science and Technology of Hu'nan Provincial Transportation Department [201835]
- Intramural Research Program, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health
Ask authors/readers for more resources
Surgical resection is the primary and most effective treatment for most patients with solid tumors. However, patients suffer from postoperative recurrence and metastasis. In the past years, emerging nanotechnology has led the way to minimally invasive, precision and intelligent oncological surgery after the rapid development of minimally invasive surgical technology. Advanced nanotechnology in the construction of nanomaterials (NMs) for precision imaging-guided surgery (IGS) as well as surgery-assisted synergistic therapy is summarized, thereby unlocking the advantages of nanotechnology in multimodal IGS-assisted precision synergistic cancer therapy. First, mechanisms and principles of NMs to surgical targets are briefly introduced. Multimodal imaging based on molecular imaging technologies provides a practical method to achieve intraoperative visualization with high resolution and deep tissue penetration. Moreover, multifunctional NMs synergize surgery with adjuvant therapy (e.g., chemotherapy, immunotherapy, phototherapy) to eliminate residual lesions. Finally, key issues in the development of ideal theranostic NMs associated with surgical applications and challenges of clinical transformation are discussed to push forward further development of NMs for multimodal IGS-assisted precision synergistic cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available